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Abstract 
Introduction: Over the past year, 3 agents have been approved for the treatment of 
melanoma by the Food and Drug Administration. These include pegylated interferon α-2b 
for stage III melanoma, vemurafenib for unresectable or metastatic melanoma with BRAF 
V600E mutation, and ipilimumab for unresectable or metastatic melanoma. Case Presenta-
tion: We present here the case of a 65-year-old Caucasian male diagnosed with advanced 
melanoma in April 2011 and treated with ipilimumab (Yervoy
®
), a monoclonal antibody 
targeting cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), as second-line treatment 
after progression with dacarbazine, for (wild-type BRAF) metastatic melanoma. The patient 
was referred to us for several painful lumps on his right arm. A biopsy of one of them 
revealed melanoma. CT and PET scans did not show any other lesions or a primary site. The 
patient was started on first-line chemotherapy with dacarbazine 850 mg/m
2
 on day 1, every 3 
weeks. After 3 cycles, the patient showed disease progression with an increase in size of the 
skin metastasis. Second-line treatment was started with ipilimumab 3 mg/kg on day 1, every 
3 weeks. At the end of the treatment, after 4 cycles, we documented a complete clinical 
response with total resolution of the skin metastasis. At the time of writing this paper, our 
patient had finished his treatment more than 9 months earlier and is still in complete 
remission. Conclusion: This is a paradigmatic case where, despite extensive metastatic 
disease, treatment with ipilimumab has confirmed its efficacy. It is still an open question why 
only a minority of patients have such a remarkable response, and further trials are warranted 
to address this important question. 
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Introduction 
About 200,000 cases of melanoma are diagnosed and 48,000 melanoma-related deaths 
occur worldwide each year [1]. Among cancers in patients under 40 years of age, the 
incidence of melanoma is second only to that of breast cancer in women and leukemia in 
men [2]. 
Since 2010, a real breakthrough has occurred in advanced melanoma therapy that had 
been anticipated for decades. Molecular targeted therapy has been added to the treatment 
regimen of this disease. Before 2010, no systemic therapy had been shown to improve 
overall survival among patients with metastatic melanoma. Ipilimumab, a monoclonal 
antibody targeting cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), and vemurafenib, 
a selective BRAF inhibitor, have both been shown to improve survival among patients with 
metastatic melanoma in randomized trials [3–5]. 
Here, we present the case of a 65-year-old Caucasian male diagnosed with advanced 
melanoma in April 2011 and treated with ipilimumab, after dacarbazine failed, for (wild-
type BRAF) metastatic disease. 
Case Report 
The patient was referred to us in April 2011, presenting with several painful exophytic 
lesions on his right arm (fig. 1, fig. 2). There was no medical history of previous cancer 
and/or melanoma. An initial CT scan was followed by a PET scan. No evidence of any 
primary tumors was found despite confirmation of multiple lumps in his right arm. A biopsy 
was carried out and revealed wild-type BRAF malignant melanoma. 
The patient was started on dacarbazine 850 mg/m2 on day 1, every 3 weeks, but after 3 
cycles he experienced disease progression with nearly all previous lesions increasing in size 
and a new one popping up. He was then started on ipilimumab 3 mg/kg and, after the whole 
treatment consisting of 4 cycles, which he tolerated very well, he achieved a complete 
clinical (fig. 3, fig. 4) and radiological response. The latest CT scan (performed at the end of 
March 2013) did not show any metastatic disease. 
Molecular targeted therapies (e.g. BRAF inhibitors) have reached high response rates 
but, unfortunately, rather short response duration (progression-free survival: 6 months), 
while immunotherapy has shown slower but more durable results [6]. Attia et al. [7] 
reported that ipilimumab (3 mg/kg every 3 weeks or an initial dose of 3 mg/kg then 1 
mg/kg every 3 weeks) plus a peptide vaccine resulted in 2 complete responses and 5 partial 
responses among 56 patients with progressive stage IV melanoma. It is rare but not 
impossible to achieve a complete response, and some patients are currently in a state of 
complete response. To date, our patient has been free from cancer for 9 months. 
Written informed consent was obtained from the patient for publication of this work 
and accompanying images. A copy of the written consent form is available for review from 
the editor-in-chief of this journal. 
Conclusion 
This is a paradigmatic case where, despite extensive metastatic disease, the treatment 
with ipilimumab has confirmed its efficacy. It is still an open question why only a minority of 
patients have such a remarkable response, and further trials are warranted to address this 
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important question. Understanding the biology of melanoma is crucial for an accurate 
selection of patients who will be more likely to benefit from ipilimumab. 
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Fig. 1. Right arm, skin metastasis at presentation. 
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Fig. 2. Right arm, skin metastasis at presentation. 
 
 
 
Fig. 3. Right arm, complete clinical response at the end of the treatment. 
 
 
 
Fig. 4. Right arm, complete clinical response at the end of the treatment. 
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